Search Within

Martin Stuart Tallman

  1. "2017"
Formats
  1. Meeting Abstract (34)
  2. Journal Article (27)
Groups
  1. Adult Leukemia (61)
  2. Center for Hematologic Malignancies (61)
  3. Department of Medicine (61)
  4. Hematologic Malignancies, Division of (61)
  5. Executive Committee, Center for Hematologic Malignancies (15)
  6. GSK Faculty (15)

More Groups

People
  1. Eytan Stein (16)
  2. Ross Levine (12)
  3. Sean Devlin (8)
  4. Jae Park (6)
  5. Bartlomiej Getta (4)
  6. Yanming Zhang (4)

More People

Years
  1. 2017 (61)
Publications
  1. Blood (32)
  2. Journal of Clinical Oncology (5)
  3. Biology of Blood and Marrow Transplantation (4)
  4. Annals of Hematology (3)
  5. Leukemia (3)
  6. Haematologica (2)

More Publications

Publishers
  1. American Society of Hematology (32)
  2. American Society of Clinical Oncology (5)
  3. Nature Publishing Group (5)
  4. Elsevier Inc. (4)
  5. Springer (3)
  6. Elsevier Ltd (2)

More Publishers

Results (61)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prospective study of acute myeloid leukemia (AML) clinical epidemiology and cytogenetic risk group in older adults in the ECOG-ACRIN E2906 clinical trial: The Acute Leukemia Epidemiology, Survival and Endpoints (ALESE) study
    Meeting Abstract

    Foran, J. M.; Zhang, Y.; Heckman, M.; Luger, S.; Hulshizer, C.; Vargas, E.; Litzow, M. R.; Altman, J. K.; Pratz, K.; Mattison, R.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations
    Meeting Abstract

    Durham, B. H.; Getta, B.; Dietrich, S.; Taylor, J.; Won, H.; Bogenberger, J. M.; Scott, S. N.; Kim, E.; Chung, Y. R.; Chung, S. S.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Widespread use of measurable residual disease in acute myeloid leukemia practice
    Meeting Abstract

    Epstein-Peterson, Z. D.; Devlin, S. M.; Stein, E. M.; Estey, E. H.; Tallman, M. S.
    Blood (2017)

    Fulltext@MSK | Save
  • Myeloid malignancies following luminal gastrointestinal cancer: High incidence of deletion 5q and DNTM3A mutations
    Meeting Abstract

    Epstein-Peterson, Z. D.; Devlin, S. M.; Stein, E. M.; Klimek, V. M.; Saltz, L. B.; Tallman, M. S.
    Blood (2017)

    Fulltext@MSK | Save
  • A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: Results from part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML)
    Meeting Abstract

    Dawson, M.; Stein, E. M.; Huntly, B. J. P.; Karadimitris, A.; Kamdar, M.; de Larrea, C. F.; Dickinson, M. J.; Yeh, P. S. H.; Daver, N.; Chaidos, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic impact of NPM1/FLT3-ITD genotypes from randomized patients with acute myeloid leukemia (AML) treated within the international ratify study
    Meeting Abstract

    DoĢˆhner, K.; Thiede, C.; Larson, R. A.; Prior, T. W.; Marcucci, G.; Jones, D.; Krauter, J.; Heuser, M.; Lo Coco, F.; Ottone, T.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Targeted deep sequencing in untreated progressive CLL helps to better dissect the genomic landscape and shows novel associations between mutations, prognostic and clinical parameters: Data from E1912, a randomized phase III study of the ECOG-ACRIN cancer research group
    Meeting Abstract

    Braggio, E.; Wang, V.; Bruins, L. A.; Barrio, S.; Lesnick, C.; Barrientos, J. C.; O'Brien, S. M.; Tallman, M. S.; Litzow, M. R.; Fonseca, R.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • National survey demonstrates practice gaps in cytogenetic and molecular testing in acute myeloid leukemia
    Meeting Abstract

    Altman, J. K.; Denzen, E.; Block, A. W.; Hasserjian, R. P.; Klepin, H.; Medeiros, B. C.; Noe, A.; Scales, W. E.; Tallman, M. S.; Wiley, K.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Ivosidenib or enasidenib combined with standard induction chemotherapy is well tolerated and active in patients with newly diagnosed AML with an IDH1 or IDH2 mutation: Initial results from a phase 1 trial
    Meeting Abstract

    Stein, E. M.; DiNardo, C. D.; Mims, A. S.; Savona, M. R.; Pratz, K.; Stein, A. S.; Fathi, A. T.; Stone, R. M.; Pollyea, D. A.; Odenike, O.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Ivosidenib (AG-120) in mutant IDH1 AML and advanced hematologic malignancies: Results of a phase 1 dose escalation and expansion study
    Meeting Abstract

    DiNardo, C. D.; De Botton, S.; Stein, E. M.; Roboz, G. J.; Mims, A. S.; Pollyea, D. A.; Swords, R. T.; Altman, J. K.; Collins, R. H.; Mannis, G. N.; more...
    Blood (2017)

    Fulltext@MSK | Save